AUTHOR=Privé Bastiaan M. , Muselaers Constantijn H. J. , van Oort Inge M. , Janssen Marcel J. R. , Peters Steffie M. B. , van Gemert Willemijn A. M. , Uijen Maike J. M. , Schilham Melline M. G. , Sedelaar J. P. Michiel , Westdorp Harm , Mehra Niven , Gotthardt Martin , Barentsz Jelle O. , Gerritsen Winald R. , Witjes J. Alfred , Nagarajah James TITLE=An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer JOURNAL=Frontiers in Nuclear Medicine VOLUME=2 YEAR=2022 URL=https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2022.863101 DOI=10.3389/fnume.2022.863101 ISSN=2673-8880 ABSTRACT=

177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.